MyFinsight
Home
Blog
About
Contact
Download
Download image
Marketable securities
$551,055K
(-34.98%↓ Y/Y)
Trade receivables,
net
$328,947K
(16.80%↑ Y/Y)
Cash and cash
equivalents
$226,152K
(23.07%↑ Y/Y)
Prepaid expenses and
other current assets
$75,878K
(29.27%↑ Y/Y)
Inventory
$26,605K
(7.05%↑ Y/Y)
Total current assets
$1,208,637K
(-13.45%↓ Y/Y)
Non-current marketable
securities
$649,144K
(4.80%↑ Y/Y)
Deferred tax assets, net
$293,730K
(-29.90%↓ Y/Y)
Right-of-use assets and other
non-current assets
$282,874K
(26.54%↑ Y/Y)
Property and equipment,
net
$95,524K
(-16.96%↓ Y/Y)
Goodwill
$63,684K
(0.00%↑ Y/Y)
Total assets
$2,593,593K
(-8.59%↓ Y/Y)
Total liabilities and
stockholders equity
$2,593,593K
(-8.59%↓ Y/Y)
Total stockholders
equity
$1,935,748K
(-9.16%↓ Y/Y)
Total liabilities
$657,845K
(-6.85%↓ Y/Y)
Accumulated deficit
-$215,794K
(-32.15%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$415K
(-120.65%↓ Y/Y)
Additional
paid-in-capital
$2,151,703K
(-6.12%↓ Y/Y)
Total current
liabilities
$370,975K
(-7.05%↓ Y/Y)
Non-current operating lease
liabilities
$169,541K
(-9.40%↓ Y/Y)
Other non-current
liabilities
$117,329K
(-2.22%↓ Y/Y)
Common stock, 0.001 par
value 400,000 shares...
$254K
(-7.64%↓ Y/Y)
Other current
liabilities
$100,286K
(-20.12%↓ Y/Y)
Accrued compensation
and benefits
$87,512K
(-2.49%↓ Y/Y)
Rebates and fees due to
customers
$65,892K
(13.92%↑ Y/Y)
Accrued clinical trial
liabilities
$64,804K
(12.44%↑ Y/Y)
Accrued collaboration
liabilities
$28,327K
(11.13%↑ Y/Y)
Accounts payable
$24,154K
(-43.62%↓ Y/Y)
Back
Back
Balance Sheet
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
source: myfinsight.com